Isoflavone Treatment for Prostate Cancer
Author Information
Author(s): Pendleton John M, Tan Winston W, Anai Satoshi, Chang Myron, Hou Wei, Shiverick Kathleen T, Rosser Charles J
Primary Institution: The University of Florida
Hypothesis
Isoflavone therapy would slow the rate of rise of serum PSA in patients with PSA recurrent prostate cancer after prior therapy.
Conclusion
Dietary intervention with isoflavone supplementation may have biologic activity in men with biochemical recurrent prostate cancer as shown by a decline in the slope of PSA.
Supporting Evidence
- PSA increased 56% per year before study entry and only increased 20% per year during the study.
- Six patients showed a significant decrease in the slope of PSA after treatment.
- Two patients had a significant increase in PSA slope after treatment.
Takeaway
This study tested a soy milk drink with isoflavones to see if it could help men with prostate cancer by slowing down a blood test called PSA that shows cancer activity.
Methodology
Twenty patients were treated with soy milk containing isoflavones for 12 months, and their PSA levels were measured at various time points.
Potential Biases
The study was non-randomized and non-blinded, which may introduce bias.
Limitations
The study was small and terminated early due to poor accrual, and it did not have a control group.
Participant Demographics
Twenty men with biochemical recurrent prostate cancer after previous therapy, median age 73.
Statistical Information
P-Value
0.05
Statistical Significance
p = 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website